(CercleFinance.com) – Spineway saw its turnover increase by 42% in 2023, a year that the manufacturer of implants and surgical instruments considers to be a good commercial exercise given the ‘generally unfavorable’ context.
The group, specializing in the treatment of severe spinal pathologies, recorded a turnover of 10.5 million euros last year, compared to 7.4 million euros in 2022.
Its growth was driven by the good commercial performance of products from Distimp and Spine Innovations, its two latest acquisitions.
From a geographic point of view, Europe remains the group’s leading commercial area, with 49% of turnover and the most dynamic region with growth of 78% last year.
Sales in Asia increased by 24%, followed by Latin America with growth of 23%.
In a press release, Spineway indicates that it has also intensified its investments (regulatory, R&D and marketing) in order to put itself in working order for the coming years.
The company warns that these expenses will weigh on its annual accounts, too, but that they should bring future growth.
This publication was well received on Friday on the Paris Stock Exchange, where the stock soared by 86% in the middle of the day.